1
|
Katyal N, Katsumoto TR, Ramachandran KJ, Yunce M, Muppidi S. Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy. J Clin Neuromuscul Dis 2023; 25:89-93. [PMID: 37962196 PMCID: PMC10645099 DOI: 10.1097/cnd.0000000000000457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Abstract
ABSTRACT Immune checkpoint inhibitors used to treat malignancies may lead to various immune-related adverse events (irAEs) including conditions such as myositis and myasthenia gravis (MG). Here, we describe 2 cases of myositis treated effectively with therapeutic plasma exchange (PLEX). A 64-year-old man with thymic cancer developed leg weakness and dyspnea 1 month after the second dose of nivolumab with moderate weakness in proximal and distal muscles, with elevated creatine kinase levels. Another 77-year-old man with Stage IIIB squamous cell carcinoma of the lung developed progressive proximal muscle weakness and became nonambulatory after cycle 2 of durvalumab with persistently high creatine kinase levels despite prednisone treatment. Electrophysiology revealed irritative myopathy without evidence of neuromuscular junction dysfunction and MG antibody testing was nonrevealing. With PLEX, both patients noticed rapid improvement in strength. PLEX in conjunction with other immunosuppressive agents can result in rapid improvement in irAE-myositis even in patients without associated MG.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology, Stanford University School of Medicine, Stanford, CA
| | - Tamiko R. Katsumoto
- Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
| | - Kavitha J. Ramachandran
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; and
| | - Muharrem Yunce
- Department of Pathology, Stanford University School of Medicine, Stanford, CA
| | - Srikanth Muppidi
- Department of Neurology, Stanford University School of Medicine, Stanford, CA
| |
Collapse
|
2
|
Katyal N, Halldorsdottir K, Govindarajan R, Shieh P, Muley S, Reyes P, Leung KK, Mullen J, Milani-Nejad S, Korb M, Goyal NA, Mozaffar T, Goyal N, Habib AA, Muppidi S. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve 2023; 68:762-766. [PMID: 37695277 DOI: 10.1002/mus.27974] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 08/22/2023] [Accepted: 08/23/2023] [Indexed: 09/12/2023]
Abstract
INTRODUCTION/AIMS Multiple novel therapies have been approved for patients with myasthenia gravis. Our aim is to describe the early experience of efgartigimod use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG). METHODS This multicenter retrospective study included AChR+ve gMG patients from five major neuromuscular centers who were treated with efgartigimod and had both pre- and post-efgartigimod myasthenia gravis activities of daily living (MG-ADL) scores. Information regarding MG history, concomitant treatment(s), MG-ADL and other MG-specific measures, laboratory data, and adverse events were recorded. RESULTS A total of 37 patients (M:23, F:14) with a mean age of 65.56 (±14.74) y were included in this cohort. A total of 36/37 patients completed at least one cycle and 28 patients completed at least two cycles of efgartigimod. A total of 72% (26/36) of patients had a clinically meaningful reduction (≥2 point change) in MG-ADL after the completion of the first cycle of efgartigimod (mean pre-efgartigimod 8.02) (±3.09) versus post-efgartigimod 4.33 (±3.62). Twenty-five percent (9/36) achieved minimal symptom expression status after one cycle and 25% (7/28) after the second cycle. Treatment benefit was sustained after cycle 2. Three out of four patients with thymoma in this cohort had clinically significant reductions in MG-ADL scores. Immunoglobulin G (IgG) levels decreased by about 60% (n = 10). One patient had a relapse of Clostridium difficile infection resulting in the discontinuation of therapy. Four patients had mild side effects. DISCUSSION Efgartigimod led to clinically meaningful improvement in MG-ADL in diverse AChR+ve gMG patients but treatment frequency to achieve optimal symptom control needs to be explored.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology and Neurosciences, Stanford University, Stanford, California, USA
| | | | | | - Perry Shieh
- Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA
| | - Suraj Muley
- Bob Bove Neuroscience Institute at HonorHealth, Scottsdale, Arizona, USA
| | - Phoebedel Reyes
- Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA
| | - Kenneth K Leung
- Department of Neurology and Neurosciences, Stanford University, Stanford, California, USA
| | - Jeffrey Mullen
- Departments of Neurology, University of California, Irvine, California, USA
| | - Shadi Milani-Nejad
- Departments of Neurology, University of California, Irvine, California, USA
| | - Manisha Korb
- Departments of Neurology, University of California, Irvine, California, USA
| | - Namita A Goyal
- Departments of Neurology, University of California, Irvine, California, USA
| | - Tahseen Mozaffar
- Departments of Neurology, University of California, Irvine, California, USA
- Department of Pathology and Laboratory Medicine, University of California, Irvine, California, USA
| | - Neelam Goyal
- Department of Neurology and Neurosciences, Stanford University, Stanford, California, USA
| | - Ali A Habib
- Departments of Neurology, University of California, Irvine, California, USA
| | - Srikanth Muppidi
- Department of Neurology and Neurosciences, Stanford University, Stanford, California, USA
| |
Collapse
|
3
|
Yunce M, Katyal N, Monis GF, Muppidi S. Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications. J Clin Apher 2023; 38:632-640. [PMID: 37183667 DOI: 10.1002/jca.22055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 02/20/2023] [Accepted: 04/30/2023] [Indexed: 05/16/2023]
Abstract
Neonatal Fc receptor (FcRn) blockade may represent a mechanism similar to plasma exchange (PLEX) in reducing immunoglobulin levels and thus have a broad implication for apheresis practitioners. Although only efgartigimod received FDA approval for myasthenia gravis in December 2021, multiple trials are currently underway with different FcRn therapies in a varied group of IgG antibody-mediated neurological and hematological disorders which are outlined in this review. In this review we discuss FcRn's mechanism of action, and its potential use in various neurological and non-neurological diseases. In addition, we further compare the kinetics and adverse events of PLEX and FcRn blockade. We encourage apheresis practitioners to be familiar with this class of drugs in order to better understand how these two therapies can be used either standalone, or in combination with other therapies as both FcRn antagonism and PLEX improve clinical state by reducing IgG levels and pathogenic antibodies.
Collapse
Affiliation(s)
- Muharrem Yunce
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Nakul Katyal
- Department of Neurology, Stanford University School of Medicine, Stanford, California, USA
| | - Grace Fortes Monis
- Department of Pathology, University of California Davis, Sacramento, California, USA
| | - Srikanth Muppidi
- Department of Neurology, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
4
|
Bhagavan S, ISHFAQ MF, Pullimamidi S, Sweeney M, Yelam A, Beladakere Ramaswamy S, Katyal N, bhatia K, Lybeck-Brown ET, Huang W, Jaura A, French BR, Gomez CR, Siddiq F, Qureshi AI. Abstract 5: “Early Mobilization Protocol” Can Be Initiated In The Intensive Care Unit In Acute Ischemic Stroke Patients After Receiving Intravenous Alteplase. Stroke 2022. [DOI: 10.1161/str.53.suppl_1.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Context:
Current guidelines recommend bed rest for 24 hours after receiving intravenous alteplase which may not be necessary and delay rehabilitation in a large proportion of acute ischemic stroke patients.
Objective:
To determine the feasibility of “early mobilization protocol” within the intensive care unit (ICU) in patients with acute ischemic stroke who received intravenous alteplase.
Methods:
All consecutive patients were admitted to the ICU with an acute ischemic stroke who received intravenous alteplase from October 2019-June 2021 were considered for “early mobilization protocol”. Patients≥18 years of age with minor, moderate or severe ischemic stroke (NIHSS score ≤22) were eligible and mobilization was initiated within 13-24 hours after intravenous alteplase administration. Exclusion criteria included hemodynamic instability, on mechanical ventilation, unstable neurological examination or progressive symptoms, or presence of external ventricular drain for hemorrhagic transformation within 24 hours of intravenous alteplase.
Results:
A total of 137 patients (56.8%) patients were eligible among 241 patients who were admitted to our institution with acute ischemic stroke after receiving intravenous alteplase. Mean age (±SD) was 63.4±16.6 and 66.2±17.0 years for the patients included and excluded in the early mobilization protocol, respectively. The mean NIHSS score (±SD) at baseline was 5.3±4.4 and 9.9±7.3 for the patients included and excluded in the early mobilization protocol, respectively. Early mobilization protocol was initiated at 18.3±3.6 hours in eligible patients compared with routine mobilization initiated at 41.6±19.8 hours in excluded patients (p<0.001). The mean NIHSS score (±SD) at discharge (1.0±2.2 versus 4.2±7.0, p<0.001) was significantly lower and rate of modified Rankin scale 0-1 at discharge (86.9% versus 67.3%, p=0.0003) was significantly higher in patients in the early mobilization protocol compared with those who were excluded.
Conclusion:
Early mobilization protocol in patients post intravenous alteplase treatment can be initiated in the ICU in appropriately selected patients without any adverse effects on neurological and functional outcomes.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Wei Huang
- Zeenat Qureshi Stroke Institute and Univeristy of Missouri, Columbia, MO
| | | | | | | | | | - Adnan I Qureshi
- Zeenat Qureshi Stroke Institute and Univeristy of Missouri, Columbia, MO
| |
Collapse
|
5
|
Johnson S, Katyal N, Narula N, Govindarajan R. Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis. Med Sci Monit 2021; 27:e933296. [PMID: 34707081 PMCID: PMC8562011 DOI: 10.12659/msm.933296] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background The tolerability of high-dose oral corticosteroids in patients with generalized myasthenia gravis (gMG) has not been systematically assessed. We evaluated adverse side effects (ASEs) of corticosteroid treatment in patients with gMG. Material/Methods Retrospective analysis was conducted of ASEs reported as being related to corticosteroid treatment in 39 patients with gMG who were treated with oral corticosteroids for ≥1 year. Results Median (interquartile range [IQR]) age was 60 (21) years, 53.8% of patients were women, and 66.7% were aged ≤65 years. Median (IQR) prednisone treatment duration was 14 (2) months; median (IQR) daily dose was 40 (15) mg. The median number of ASEs reported as corticosteroid-related was 2/patient (IQR, 1). Pre-diabetes and weight gain were most common (each 43.6% of patients). Bruising, insomnia, and osteoporosis were more prevalent in patients aged >65 years, while irritability, osteopenia, and pre-diabetes were more common in patients aged ≤65 years, although differences were not statistically significant. Irritability and weight gain were more prevalent in women (P=0.010 for irritability); osteoporosis and pre-diabetes more common in men (P=0.015 for osteoporosis). ASEs were generally more common in the high-dose prednisone group (>30 mg/day), but were only statistically significant for irritability (P=0.001). Conclusions Corticosteroid-related ASEs were common in patients with gMG. Some of these ASEs can have serious medical consequences, and certain ASEs appeared to be associated with specific patient characteristics. Demographics and comorbidities of patients with gMG must be carefully considered before corticosteroid initiation. Potential ASEs, such as unanticipated osteoporosis in men, require extra vigilance.
Collapse
Affiliation(s)
- Stephen Johnson
- Department of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA, USA
| | - Nakul Katyal
- Department of Neurology, University of Missouri Health Care, Columbia, MO, USA
| | - Naureen Narula
- Department of Pulmonary and Critical Care, Northwell Health - Staten Island University Hospital, New York City, NY, USA
| | - Raghav Govindarajan
- Department of Neurology, University of Missouri Health Care, Columbia, MO, USA
| |
Collapse
|
6
|
Katyal N, Singla P, Idiculla PS, Narula N, Govindarajan R. Dichlorphenamide for Refractory Hyperkalemic Periodic Paralysis. J Clin Neuromuscul Dis 2021; 23:58-59. [PMID: 34431807 DOI: 10.1097/cnd.0000000000000382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- Nakul Katyal
- Department of Neurology, University of Missouri Health Care, Columbia, MO
| | - Pratibha Singla
- Department of Neurology, Gian Sagar Medical College and Hospital, Banur, Jansla, Patiala, Punjab, India
| | - Pretty Sara Idiculla
- Department of Neurology, University of Missouri School of Medicine, Columbia, MO
| | - Naureen Narula
- Department of Pulmonology and Critical Care Medicine, Staten Island University Hospital, Staten Island, NY
| | | |
Collapse
|
7
|
Sheckley H, Malhotra K, Katyal N, Narula N, Govindarajan R. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis. J Clin Apher 2021; 36:727-736. [PMID: 34241920 DOI: 10.1002/jca.21923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/22/2021] [Accepted: 06/29/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND Despite the availability of several immunomodulatory therapies, about 20% of myasthenia gravis (MG) patients remain refractory to conventional treatments. There is limited evidence to support the use of maintenance therapeutic plasma exchange (TPE) therapy for refractory generalized MG. METHODS Retrospective chart review of 14 patients with refractory generalized MG treated for 12 months with maintenance TPE therapy. Outcome measures were myasthenia gravis composite (MGC) score, myasthenia gravis activities of daily living (MG-ADL), number of acute exacerbations, medication changes, and adverse events. Data were collected at 3 monthly intervals for 12 months before and after initiation of TPE therapy. RESULTS Clinically meaningful reductions in mean MG-ADL (>2 points) (mean MG-ADL score: 9.9 ± 0.5; 12-month pre-TPE to 5.2 ± 0.9; 12-month post-TPE) and MGC (>3 points) (mean MGC score: 25.2 ± 1.6; 12-month pre-TPE to 11.7 ± 1.4; 12-month post-TPE) were observed at 3 months following initiation of TPE and were maintained up to 12 months in all patients. After 12 months of TPE therapy, all patients had a significant reduction in daily prednisone and pyridostigmine use. Patients previously on IVIG or rituximab therapy were successfully weaned off both treatments. There was a significant reduction in acute MG exacerbations; 7.8 ± 1.1 mean exacerbations/patient (12-month pre-TPE) to 2 ± 1.1 mean exacerbations/patient (12-month post-TPE). CONCLUSION Over a period of 12 months, maintenance TPE therapy improved MG-ADL, and MGC with decreased immunosuppressant requirement, while being well-tolerated.
Collapse
Affiliation(s)
- Hunter Sheckley
- Department of Neurology, University of Missouri, Columbia, Missouri, USA
| | - Kunal Malhotra
- Division of Nephrology, Department of Internal Medicine, University of Missouri, Columbia, Missouri, USA
| | - Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, Missouri, USA
| | - Naureen Narula
- Department of Pulmonology and Critical Care Medicine, Staten Island University Hospital, Staten Island, New York, USA
| | | |
Collapse
|
8
|
Pathikonda C, Katyal N, Narula N, Govindarajan R. Disease and Patient Characteristics Contributing to Diagnostic Delays in Patients With Guillain-Barré Syndrome. Front Neurol 2021; 12:684847. [PMID: 34248826 PMCID: PMC8270000 DOI: 10.3389/fneur.2021.684847] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 06/01/2021] [Indexed: 11/13/2022] Open
Abstract
Introduction: Diagnosis of Guillain Barre syndrome (GBS) is often made clinically. Certain patient and disease characteristics can cause delays in diagnosis and management. Methods: Observational retrospective study of forty-four patients diagnosed with GBS either clinically, cerebrospinal fluid analysis, and/or by electro-diagnostic criteria at a teaching hospital (University of Missouri Hospital) in Columbia, Mid-Missouri between 2011 and 2017. Results: Patients with coexisting neurological conditions had statistically significant delay in diagnosis of GBS [Mean (SD); 13 ± 5 vs. 9.39 ± 4.7; p = 0.03]. Patients presenting with motor + symptoms (sensory and/or autonomic, in addition to motor), compared to those with only motor symptoms had statistically significant delay in diagnosis of GBS [Mean (SD); 11.90 ± 5 vs. 8.58 ± 4; p = 0.04]. Discussion: Presence of co-existing neurological conditions, and motor + symptoms can delay timely diagnosis and management of GBS.
Collapse
Affiliation(s)
| | - Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, MO, United States
| | - Naureen Narula
- Department of Pulmonology and Critical Care, Staten Island University Hospital, New York, NY, United States
| | - Raghav Govindarajan
- Department of Neurology, University of Missouri, Columbia, MO, United States
| |
Collapse
|
9
|
Digala L, Katyal N, Narula N, Govindarajan R. Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report. Front Neurol 2021; 12:660741. [PMID: 34025563 PMCID: PMC8134535 DOI: 10.3389/fneur.2021.660741] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 03/24/2021] [Indexed: 11/21/2022] Open
Abstract
Objective: To report the case of a 35-year-old woman with treatment-resistant aquaporin-4 (AQP-4) immunoglobulin G (IgG) seronegative neuromyelitis optica spectrum disorder (NMOSD) successfully treated with eculizumab (a terminal complement inhibitor). Methods: The investigational procedures and treatment regimens the patient received were documented over 8 years [2012 (first presentation) to 2020]. Results: The patient presented with subacute onset of lower-limb weakness and numbness, gait imbalance, and urinary incontinence. Magnetic resonance imaging (MRI) showed abnormalities in the thoracic spine from T7 to T10, but brain and cervical spine scans, visual evoked potential latencies, and IgG index were normal; cerebrospinal fluid pleocytosis and oligoclonal bands were both present. After treatment with intravenous methylprednisolone 1 g/day for 5 days, the patient was discharged without medication to acute rehabilitation but experienced relapses from 2012 to 2014. She was treated with oral prednisone (initiated at 40 mg/day in 2014; the dose was halved in 2015 due to weight gain) and mycophenolate mofetil (MMF) 1 g twice daily (from June 2015), but between 2014 and 2019 experienced 4–5 relapses/year, requiring treatment with intravenous methylprednisolone, with added maintenance plasma exchange from 2018 onwards. Although the patient tested negative for antibodies to AQP-4 and myelin oligodendrocyte glycoprotein, she was diagnosed with NMOSD in February 2017, based on recurrent episodes of longitudinal extensive transverse myelitis, MRI changes, and area postrema syndrome. By 2018 the patient needed a cane to walk. Prednisone and MMF were discontinued mid-2018, and rituximab was prescribed from July 2018 (maintenance regimen two 1 g doses 2 weeks apart every 6 months) but discontinued in July 2019 owing to lack of significant improvement. From July 2019 eculizumab was prescribed for 6 months (900 mg weekly for the first four doses, then 1200 mg every 2 weeks). The patient had no relapses or adverse events during and after eculizumab treatment (as of August 2020) and was able to walk unaided; her Expanded Disability Status Scale score improved from 4–5 during 2015–2018 to 2 in 2020 following eculizumab treatment. Conclusion: Eculizumab shows promise as a treatment for AQP-4 IgG-seronegative NMOSD and further studies are warranted.
Collapse
Affiliation(s)
- Lakshmi Digala
- Department of Neurology, University of Missouri Health Care, Columbia, MO, United States
| | - Nakul Katyal
- Department of Neurology, University of Missouri Health Care, Columbia, MO, United States
| | - Naureen Narula
- Department of Pulmonary and Critical Care, Northwell Health - Staten Island University Hospital, New York, NY, United States
| | - Raghav Govindarajan
- Department of Neurology, University of Missouri Health Care, Columbia, MO, United States
| |
Collapse
|
10
|
Narula N, Katyal N, Salem M, Avula A, Siddiqui A, Maroun R, Chalhoub M. A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients. Respir Med Case Rep 2021; 34:101420. [PMID: 34354918 PMCID: PMC8322142 DOI: 10.1016/j.rmcr.2021.101420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 03/30/2021] [Accepted: 04/27/2021] [Indexed: 11/23/2022] Open
Abstract
Indwelling Pleural Catheters (IPC) are increasingly being used for management of recurrent pleural effusions (RPEs). Use of IPC for management of both malignant and non-malignant recurrent pleural effusions has been associated with complications such as dysfunctional or nonfunctioning IPCs. Alteplase, a tissue plasminogen activator (tPA) is often used to restore flow of non-draining IPC in symptomatic patients. We present a case of a sixty-eight-year old patient with life-threatening pleural hemorrhage following intrapleural catheter instillation of tPA that was managed successfully by thoracotomy. Our case describe the importance of individualizing the fibrinolytic dose, frequency and the indwelling time in high risk patients. We have reviewed the current literature and recommendations for use of fibrinolytic therapy for IPC in high risk patients on anticoagulation.
Collapse
Affiliation(s)
- Naureen Narula
- Department of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA
| | - Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, MO, USA
| | - Mohammed Salem
- Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA
| | - Akshay Avula
- Department of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA
| | - Abdulhassan Siddiqui
- Department of Pulmonary and Critical Care, Christie Clinic, Champagne, Illinois, USA
| | - Rabih Maroun
- Department of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA
| | - Michel Chalhoub
- Department of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA
| |
Collapse
|
11
|
Katyal N, Narula N, Govindarajan R. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. J Neuromuscul Dis 2021; 8:287-294. [PMID: 33325394 PMCID: PMC8075396 DOI: 10.3233/jnd-200584] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Although established therapies are effective in most patients with generalized myasthenia gravis (gMG), some patients do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted therapies for treatment-refractory gMG. Objective: To describe real-world experience with eculizumab in patients with treatment-refractory acetylcholine receptor antibody-positive (AChR+) gMG. Methods: Retrospective chart review of 15 patients with treatment-refractory AChR+ gMG treated for 12 months with eculizumab (900 mg/week for 4 weeks then 1200 mg every 2 weeks). Outcome measures were Myasthenia Gravis–Activities of Daily Living (MG-ADL) scores, number of exacerbations, single-breath count test (SBCT) score, medication changes, selected Quantitative Myasthenia Gravis (QMG) evaluations, and adverse events. Data collected at 3-monthly intervals for 12 months before and after eculizumab initiation were analyzed. Results: Clinically meaningful reductions in total MG-ADL scores were observed at 3 months following eculizumab initiation and maintained up to 12 months in all patients. After 12 months’ eculizumab treatment, there was a significant reduction in the number of acute exacerbations; mean (SD) SBCT score improved from 28.13 (0.33) to 50.26 (2.86); all patients achieved a ‘none’ or ‘mild’ rating for QMG evaluations; all patients reduced their daily prednisone dose; and nine patients had discontinued pyridostigmine. At the end of treatment, intravenous immunoglobulin was discontinued in all six patients receiving this therapy at eculizumab initiation. Eculizumab was well tolerated. Conclusions: This real-world study demonstrated improvement in outcome measures and decreased concomitant drug requirement within 12 months of eculizumab initiation in patients with treatment-refractory AChR+ gMG.
Collapse
Affiliation(s)
- Nakul Katyal
- University of Missouri Health Care, Columbia, Missouri, USA
| | - Naureen Narula
- University of Missouri Health Care, Columbia, Missouri, USA
| | | |
Collapse
|
12
|
Narula N, Joseph R, Katyal N, Daouk A, Acharya S, Avula A, Maroun R. Seizure and COVID-19: Association and review of potential mechanism. Neurol Psychiatry Brain Res 2020; 38:49-53. [PMID: 33071468 PMCID: PMC7553058 DOI: 10.1016/j.npbr.2020.10.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 10/09/2020] [Indexed: 12/22/2022]
Abstract
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, this highly transmissible virus has since spread rapidly around the world. Though respiratory complication is the primarily reported manifestation though rare, yet serious neurological complications are being frequently reported in the literature. In selected coronavirus disease-2019 (COVID-19) cases neurologic complications may manifest as seizures. In this paper, we have reviewed current literature on seizures linked with SARS- COV 2 infection including published or pre-print original articles, review articles, and case reports. We have discussed the electroencephalogram (EEG), imaging, and Cerebrospinal fluid (CSF) findings in patients with COVID-19 presenting with seizure. We will be concluding the paper by briefly discussing the three mechanisms by which seizures can develop in patients infected with SARS- COV 2 - (a) Direct Mechanism (b) Indirect Mechanism and (c) Exacerbation of Seizure in Patients with Epilepsy (PWE). Our aim is to update the physicians working with COVID-19 patients about this potential complication and hope that understanding of these proposed mechanisms can provide an opportunity for the physicians for early diagnosis or even better, help prevent this complication.
Collapse
Affiliation(s)
- Naureen Narula
- Department of Pulmonary and Critical Care Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| | - Rudman Joseph
- Department of Internal Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| | - Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, MO, USA
| | - Aref Daouk
- Department of Pulmonary and Critical Care Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| | - Sudeep Acharya
- Department of Internal Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| | - Akshay Avula
- Department of Internal Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
- Department of Pulmonary and Critical Care Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| | - Rabih Maroun
- Department of Pulmonary and Critical Care Medicine, Northwell Health- Staten Island University Hospital, Staten Island, NY, USA
| |
Collapse
|
13
|
Avula A, Nalleballe K, Toom S, Siddamreddy S, Gurala D, Katyal N, Maddika S, Polavarapu AD, Sharma R, Onteddu S. Incidence of Thrombotic Events and Outcomes in COVID-19 Patients Admitted to Intensive Care Units. Cureus 2020; 12:e11079. [PMID: 33224673 PMCID: PMC7678760 DOI: 10.7759/cureus.11079] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Introduction While coronavirus disease 2019 (COVID-19) mostly causes respiratory illnesses, emerging evidence has shown that patients with severe COVID-19 can develop complications like venous thromboembolism (VTE) and arterial thrombosis as well. The incidence of thrombosis among critically ill patients in the literature has been highly variable, ranging from 25 to 69%. Similarly, reported mortality among critically ill patients has been highly variable too, and it has ranged from 30 to 97%. In this study, we analyzed data from a large database to address the incidence, the risk factors leading to thrombotic complications, and mortality rates among COVID-19 patients. Material and methods Data were obtained from TriNetX (TriNetX, Inc., Cambridge, MA), a multinational clinical research platform that collects medical records from 42 healthcare organizations (HCOs). All nominal data were compared using the chi-squared test. Alpha of <0.05 was considered statistically significant. We used Benjamini-Hochberg correction with a false discovery rate of 0.1 to correct for multiple comparisons. Results We identified 18,652 COVID-19-positive patients, with a median age of 50.7 years [interquartile range (IQR): 31.8-69.6]; among them, 51.8% (9,672) were males and 48.2% (8,951) were females. Of these patients, 630 [3.37%; median age: 61 years (IQR: 44.9-77.1)] were critically ill, requiring intensive care unit (ICU) care within one month of their diagnosis. Men were over-represented among the ICU patients when compared to women (3.7% vs 3%, p=0.009, Χ2=6.66). African Americans were over-represented among the ICU patients when compared to Caucasians (8.5% vs 4%, p<0.0001, Χ2=76.65). Older patients, i.e., 65 years and older, were over-represented in the ICU compared to patients aged 18-64 years (6.8% vs 2.5%, p<0.0001, Χ2=121.43). The cumulative incidence of thrombotic events in the ICU population was 20.4% (129/630). Thrombotic events were significantly more common in patients who were 65 years and older when compared to patients in the age group of 18-64 years (24.6% vs 17.31%, p=0.02, Χ2=5.38). Mortality among ICU patients was higher in those who were 65 years and older when compared to the age group of 18-64 years (31.9% vs 17.3% p=0.0003, Χ2=18.41). The overall mortality in the study population was higher in patients who were 65 years and older when compared to patients aged 18-64 years (18.55% vs 1.4%, p<0.0001, Χ2=1915). Conclusions Among COVID-19 patients, men, African Americans, and people who are 65 years and older are more likely to have severe disease and require ICU level of care. Patients who are 65 years and older are more likely to have thrombotic events, myocardial infarction (MI), and stroke. Overall mortality and ICU mortality are higher among COVID-19 patients who are 65 years and older.
Collapse
Affiliation(s)
- Akshay Avula
- Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, USA
| | - Krishna Nalleballe
- Neurology/Stroke, University of Arkansas for Medical Sciences, Little Rock, USA
| | - Sudhamshi Toom
- Hematology and Medical Oncology, Maimonides Medical Center, Brooklyn, USA
| | | | - Dhineshreddy Gurala
- Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, USA
| | - Nakul Katyal
- Neurology, University of Missouri, Columbia, USA
| | - Srikanth Maddika
- Internal Medicine, St. Barnabas Hospital Health System, Bronx, USA
| | - Abhishek D Polavarapu
- Gastroenterology and Hepatology, Northwell Health - Staten Island University Hospital, Staten Island, USA
| | - Rohan Sharma
- Neurology/Stroke, University of Arkansas for Medical Sciences, Little Rock, USA
| | - Sanjeeva Onteddu
- Neurology/Stroke, University of Arkansas for Medical Sciences, Little Rock, USA
| |
Collapse
|
14
|
Katyal N, Narula N, Acharya S, Govindarajan R. Neuromuscular Complications With SARS-COV-2 Infection: A Review. Front Neurol 2020; 11:1052. [PMID: 33041989 PMCID: PMC7527465 DOI: 10.3389/fneur.2020.01052] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 08/11/2020] [Indexed: 12/21/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases were first reported in Wuhan, Hubei province of China in December, 2019. SARS- COV-2 primarily affects the cardio-respiratory system. Over the last few months, several studies have described various neurological sequelae of SARS-COV-2 infection. Neurological complications are more frequent in patients with severe respiratory infections. In this review, we have analyzed the current literature on neuromuscular complications associated with SARS-COV-2 and highlighted possible mechanisms of neuromuscular invasion. We reviewed 11 studies describing 11 cases of Guillain Barre syndrome (GBS), and 1 case each of Miller Fisher syndrome, Polyneuritis Cranialis, Acute myelitis, Oculomotor paralysis and Bell's Palsy associated with SARS-COV-2 infection. Mean age of patients with GBS was 61.54 years, with standard deviation (SD) 14.18 years. Majority patients had fever and cough as the first symptom of SARS COV-2 infection. Mean time for onset of neurological symptoms from initial symptoms in 11 patients was 8.18 days, with SD of 2.86 days. Mean time to performing electrodiagnostic study from onset of neurological symptom was 6 days with standard deviation of 3.25. Six patients had demyelinating pattern, three had acute sensory motor axonal neuropathy, and one had acute motor axonal neuropathy on electrodiagnostic studies.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, MO, United States
| | - Naureen Narula
- Department of Pulmonary- Critical Care Medicine, Staten Island University Hospital, New York, NY, United States
| | - Sudeep Acharya
- Department of Internal Medicine, Staten Island University Hospital, New York, NY, United States
| | - Raghav Govindarajan
- Department of Neurology, University of Missouri, Columbia, MO, United States
| |
Collapse
|
15
|
Katyal N, Singh I, Narula N, Idiculla PS, Premkumar K, Beary JM, Nattanmai P, Newey CR. Continuous Electroencephalography (CEEG) in Neurological Critical Care Units (NCCU): A Review. Clin Neurol Neurosurg 2020; 198:106145. [PMID: 32823186 DOI: 10.1016/j.clineuro.2020.106145] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 07/20/2020] [Accepted: 08/07/2020] [Indexed: 12/17/2022]
Affiliation(s)
- Nakul Katyal
- University of Missouri, Department of Neurology, 5 Hospital Drive, CE 540, United States.
| | - Ishpreet Singh
- University of Missouri, Department of Neurology, 5 Hospital Drive, CE 540, United States.
| | - Naureen Narula
- Staten Island University Hospital, Department of Pulmonary- critical Care Medicine, 475 Seaview Avenue Staten Island, NY, 10305, United States.
| | - Pretty Sara Idiculla
- University of Missouri, Department of Neurology, 5 Hospital Drive, CE 540, United States.
| | - Keerthivaas Premkumar
- University of Missouri, Department of biological sciences, Columbia, MO 65211, United States.
| | - Jonathan M Beary
- A. T. Still University, Department of Neurobehavioral Sciences, Kirksville, MO, United States.
| | - Premkumar Nattanmai
- University of Missouri, Department of Neurology, 5 Hospital Drive, CE 540, United States.
| | - Christopher R Newey
- Cleveland clinic Cerebrovascular center, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
| |
Collapse
|
16
|
Abstract
Central venous catheter (CVC) insertion is extensively utilized in Intensive Care Units for evaluation of hemodynamic status, administration of intravenous drugs, and for providing nutritional support in critically ill patients. Unfortunately, CVC use is associated with complications including lung injury, bleeding, infection, and thrombosis. We present a patient with an acute ischemic stroke from an inadvertently placed CVC into the right common carotid artery. A 57-year-old male presented to our institution for left hemiplegia and seizures 2 days after a CVC was placed. He was found to have a right frontal ischemic stroke on computed tomography (CT). CT angiography noted that the catheter was arterial and had a thrombosis around it. He was started on a low-dose heparin infusion. A combination of cardiothoracic surgery and interventional cardiology was required to safely remove the catheter. Central arterial catheterization is an unusual cause for acute ischemic stroke and presents management challenges.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology, University of Missouri, Columbia 63511, MO, USA
| | - Amanda Korzep
- Department of Emergency Medicine, University of Missouri, Columbia 63511, MO, USA
| | - Christopher Newey
- Department of Neurology, University of Missouri, Columbia 63511, MO, USA
| |
Collapse
|
17
|
Kaur H, Katyal N, Yelam A, Kumar K, Srivastava H, Govindarajan R. Malignant Hyperthermia. Mo Med 2019; 116:154-159. [PMID: 31040503 PMCID: PMC6461318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Malignant Hyperthermia (MH) is a life-threatening pharmacogenetic disorder which results from exposure to volatile anesthetic agents and depolarizing muscle relaxants. It manifests as a hypermetabolic response resulting in tachycardia, tachypnea, hyperthermia, hypercapnia, acidosis, muscle rigidity and rhabdomyolysis. An increase in the end-tidal carbon dioxide is one of the earliest diagnostic signs. Dantrolene sodium is effective in the management of MH, and should be available whenever general anesthesia is administered. This review also aims to highlight the genetics and pathology of MH, along with its association with various inherited myopathy syndromes like central core disease, multi-mini core disease, Native-American myopathy, and King-Denborough syndrome.
Collapse
Affiliation(s)
- Harleen Kaur
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| | - Nakul Katyal
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| | - Anudeep Yelam
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| | - Keerthana Kumar
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| | - Hirsch Srivastava
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| | - Raghav Govindarajan
- Harleen Kaur, MBBS, Nakul Katyal, MD, Anudeep Yelam, MBBS, Keerthana Kumar, MBBS, and Raghav Govindarajan, MD, MSMA member since 2013, are in the Department of Neurology, University of Missouri School of Medicine
| |
Collapse
|
18
|
Katyal N, Yerram S, Sarwal A, George P, Newey C. Lateralized periodic discharges are predictive of seizures in patients with intracerebral hemorrhage. Ann Indian Acad Neurol 2019; 22:414-418. [PMID: 31736561 PMCID: PMC6839323 DOI: 10.4103/aian.aian_154_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 04/29/2018] [Accepted: 05/03/2018] [Indexed: 11/30/2022] Open
Abstract
Background: Patients with intracerebral hemorrhages (ICHs) have higher incidence of seizures. Previous studies have suggested that location and size of hemorrhage may increase epileptogenicity. We aim to evaluate seizure development risk factors from clinical examination, imaging, and continuous electroencephalography (cEEG) in critically ill patients with ICH. Methods: We reviewed 57 consecutive patients with ICH admitted to a neurocritical intensive care unit over a 24-month period who were monitored on cEEG. Their demographic and examination data, ICH score, Glasgow Coma Scale (GCS), location of bleed, cEEG patterns, and discharge status were analyzed. Results: Sixteen (28%) patients from our study cohort had seizures at a mean duration of 7.46 h from cEEG hookup. Fifteen (93%) of those patients had only electrographic seizures. The finding of lateralized periodic discharges (LPDs) was significantly (P = 0.019) associated with seizures. Other variables, such as ICH score, size and location of hemorrhage, GCS, mental status, and other cEEG patterns, were not significantly associated with seizures. Conclusion: We found that LPDs were predictive of seizures in ICH patients. cEEG for longer than 24 h is preferred for detection of seizures as they occurred at a mean later than 7 h and most were without clinical signs.
Collapse
|
19
|
Katyal N, George P, Nattanamai P, Raber LN, Beary JM, Newey CR. Improvement in Sonographic Vasospasm Following Intravenous Milrinone in a Subarachnoid Hemorrhage Patient with Normal Cardiac Function. Cureus 2018; 10:e2916. [PMID: 30186721 PMCID: PMC6122655 DOI: 10.7759/cureus.2916] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Cerebral vasospasm and delayed cerebral ischemia are well-known complications of an aneurysmal subarachnoid hemorrhage (aSAH), generally occurring days to weeks after hemorrhagic ictus. Management strategies for these complications are controversial and vary in efficacy. There is a growing interest in supporting the use of intravenous (IV) milrinone to manage vasospasm. A 31-year-old male presented to the hospital after being found down outside his home. Computed tomography (CT) of the head and subsequent CT angiogram revealed a Fisher Grade 4 aneurysmal subarachnoid hemorrhage (aSAH). Six hours after admission, he became hypotensive and his neurological examination declined. A repeat CT head showed a new, left frontoparietal intracerebral hemorrhage (ICH) along with increasing SAH. He was stabilized with vasopressors and underwent emergent decompressive hemicraniectomy with subsequent clipping of the aneurysm. Approximately one week later, transcranial Doppler (TCD) showed increasing mean flow velocities in the bilateral anterior and middle cerebral arteries consistent with cerebral vasospasm. He was treated with intravenous milrinone. Repeat TCD 6.5 hours after the initial TCD showed improved mean flow velocities. His cardiac function by echocardiogram assessment was normal. The decrease in TCD velocity following treatment with milrinone indicates an improvement in the cerebral vasospasm regardless of cardiac output in a patient with subarachnoid hemorrhage. This case suggests that augmenting cardiac output may not be the only mechanism for the therapeutic benefit of milrinone.
Collapse
Affiliation(s)
- Nakul Katyal
- Neurology, University of Missouri, Columbia, USA
| | | | | | | | - Jonathan M Beary
- Neurobehavioral Sciences, A. T. Still University, Kirksville, USA
| | | |
Collapse
|
20
|
Lam H, Katyal N, Parker C, Natteru P, Nattanamai P, Newey CR, Kraus CK. Thromboelastography With Platelet Mapping is Not an Effective Measure of Platelet Inhibition in Patients With Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy. Cureus 2018; 10:e2515. [PMID: 29942718 PMCID: PMC6015994 DOI: 10.7759/cureus.2515] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Thromboelastography with platelet mapping (TEG-PM) is a modality to measure platelet function, especially in patients taking antiplatelet medications. It consists of two components: arachidonic acid (AA), which is sensitive to aspirin, and adenosine diphosphate (ADP), which is sensitive to clopidogrel. In patients with spontaneous intracerebral hemorrhages (sICH), the clinical interpretation of platelet mapping is unclear. The objective of this study was to evaluate TEG-PM in patients with sICH on aspirin and/or clopidogrel who receive platelet transfusions. This study was an IRB-approved, retrospective case-control study over three years at an academic medical center. Adult patients with sICH were included if they had an admission computed tomography head (CTH) and platelet mapping followed by a repeat platelet mapping and CTH post platelet transfusion. A threshold of 50% inhibition was used as the benchmark for both ADP and AA inhibition. Around 248 subjects with sICH were identified, and 107 were excluded for incomplete documentation, leaving 141 for analysis. Of these, nine met our inclusion criteria. No statistical significance was found on the antithrombotic effects of aspirin or clopidogrel on TEG-PM (p=1.00 for both). Sensitivity and specificity of TEG-PM for clopidogrel was 100% and 42.9%, respectively, and 80% and 0%, respectively, for aspirin. Platelet transfusion did not significantly change AA or ADP inhibition (p=1.00). Hemorrhagic expansion on CTH was not associated with a decrease AA or ADP inhibition (p=1.00). TEG-PM is not an effective measure of platelet inhibition in sICH patients who were on antiplatelet medications and is not a reliable measurement following platelet transfusion.
Collapse
Affiliation(s)
- Helena Lam
- University of Missouri School of Medicine, Columbia, USA
| | - Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, USA
| | | | - Prashant Natteru
- Department of Neurology, University of Mississippi Medical Center, Jackson, USA
| | | | | | - Chadd K Kraus
- Emergency Medicine, Geisinger Health System, Danville, USA
| |
Collapse
|
21
|
Katyal N, Narula N, George P, Nattanamai P, Newey CR, Beary JM. Delayed Post-hypoxic Leukoencephalopathy: A Case Series and Review of the Literature. Cureus 2018; 10:e2481. [PMID: 29922522 PMCID: PMC6003800 DOI: 10.7759/cureus.2481] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Delayed post-hypoxic leukoencephalopathy (DPHL) is a unique clinical entity that presents with cognitive impairment days to weeks after an episode of acute hypoxic brain injury. Frequently hypoxia is unrecognized as a mechanism for clinical decline and extensive workup ensues. We present two cases of DPHL highlighting the neuroimaging findings. In both patients, a cerebral hypoxic event was followed by a recovery phase with subsequent delayed clinical decline. Patient 1 suffered hypoxia from drug-induced respiratory depression and lack of post-operative positive airway pressure (PAP) support. Her neurological exam on follow-up revealed progressive cognitive decline. Magnetic resonance imaging (MRI) brain showed bilateral white matter changes involving the centrum semiovale. Patient 2 developed a generalized tonic-clonic seizure during an endobronchial biopsy procedure and was found to have multiple air emboli on computed tomography (CT) head scan. She was initially in a drug-induced coma for her seizures. Electroencephalography (EEG) on day 14 of admission showed changes consistent with diffuse encephalopathy. MRI brain showed bilateral white matter changes particularly at the watershed zones and in the centrum semiovale. DPHL is a rare and under-recognized clinical entity that requires clinical suspicion and detailed evaluation for diagnosis. Neuroimaging studies can provide prognostic information regarding the extent of neurological injury.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, USA
| | - Naureen Narula
- Internal Medicine, Staten Island University Hospital, staten island, USA
| | | | | | | | | |
Collapse
|
22
|
Abstract
Herpes simplex-1 virus encephalitis (HSE) is the most commonly recognized cause of sporadic encephalitis in the United States. Historically HSE has been considered extremely detrimental given the associated relentless neurological deterioration secondary to cerebral edema and status epilepticus. With recent advances in antiviral therapeutics in past decades, the majority of complications can be managed effectively although the associated morbidity and mortality still remains high. The key modifiable factor determining recovery is the rapid initiation of antiviral therapy. We discuss the case of a 19-year-old female with HSE who received standard acyclovir therapy. Despite using recommended dosage and duration of acyclovir, her clinical condition worsened significantly and subsequently required multiple antiviral therapeutics and steroid therapy.
Collapse
|
23
|
Katyal N, Newey CR, George P, Nattanamai P, Beary JM, Ardelt A, Vellipuram A. Somatosensory Evoked Potentials as a Tool to Evaluate Brainstem Herniation in the Neuroscience Intensive Care Unit. Cureus 2018; 10:e2443. [PMID: 29881656 PMCID: PMC5990027 DOI: 10.7759/cureus.2443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Somatosensory evoked potentials (SSEPs) are a sensitive, minimally invasive technique used to localize dysfunction of myelinated peripheral and central axons in the nervous system. The utility of SSEPs in acutely assessing central nervous system function in brainstem herniation in the neuroscience intensive care unit (NICU) has not been well established. We discuss a case of an 18-year-old, postpartum female who presented with intermittent headache, diplopia, nausea/vomiting and cachexia following delivery two months prior. Shortly after arrival to the emergency department, she developed flaccid quadriparesis and complete ophthalmoplegia. Computed tomography (CT) of the head showed effacement of the basal cisterns along with 2 cm cerebellar tonsillar herniation into the foramen magnum concerning for intracranial hypotension. Raising the head of bed caused hemodynamic instability necessitating prolonged Trendelenburg positioning. The patient was evaluated with serial SSEPs which initially showed a bilateral low amplitude N20 response and normal N13 response. Subsequent SSEP testing showed increased N20 amplitude which correlated with clinical improvement in the patient. SSEP is a minimally invasive and sensitive method used to assess the integrity of the somatosensory nervous system pathway; SSEPs may be a useful monitoring adjunct to assess the evolution of posterior fossa lesions leading to brainstem compression.
Collapse
|
24
|
Abstract
Neuropathies can occur in patients with diffuse large B-cell lymphoma (DLBCL) at any stage of the disease as a presenting symptom or during later stages of illness. A wide spectrum of neurological association is known to occur with DLBCL, ranging from cranial nerve palsies to peripheral neuropathies. Evaluation of cranial and peripheral neuropathies in patients with DLBCL requires meticulous clinical, imaging, and electrodiagnostic testing. A 75-year-old right-handed female with a known history of multiple cranial neuropathies and DLBCL presented with acute dysphagia and upper extremity weakness of one-week duration. On evaluation, she was found to have right vagal nerve palsy. Cerebrospinal fluid (CSF) analysis along with flow cytometry testing showed CD19 and CD20 positive B cells, confirming neoplastic infiltration of CSF. We describe the case and review the literature of the association of cranial nerve palsies with DLBCL.
Collapse
Affiliation(s)
- Nakul Katyal
- Department of Neurology, University of Missouri, Columbia, Missouri
| | - Anant Wadhwa
- Department of Neurology, University of Missouri, Columbia, Missouri
| | - Pradeep C Bollu
- Department of Neurology, University of Missouri, Columbia, Missouri
| |
Collapse
|
25
|
Mullaguri N, Sarwal A, Katyal N, Nattanamai P, George P, Newey CR. Trans-cranial Doppler as an Ancillary Study Supporting Irreversible Brain Injury in a Post Cardiac Arrest Patient on Extracorporeal Membrane Oxygenation. Cureus 2018; 10:e2161. [PMID: 29644151 PMCID: PMC5889154 DOI: 10.7759/cureus.2161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
26
|
Narula N, Siddiqui F, Katyal N, Avula A, Chalhoub M. Internal Carotid Artery Dissection with Lidocaine Nerve Block Injection Trauma: A Rare Case Report. Cureus 2018. [PMID: 29531880 PMCID: PMC5837233 DOI: 10.7759/cureus.2027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Internal carotid artery dissection (ICAD) accounts for 25% of cerebrovascular accidents in young and middle-aged patients. Dissection occurs when the intimal wall of an artery is damaged as a result of trauma or defect. ICAD development after dental work is a relatively uncommon phenomenon. Our study highlights a rare presentation of ICAD that resulted from a direct lidocaine nerve block injection in a patient undergoing pulpotomy for a right maxillary second premolar tooth. We have described the case and reviewed the literature on this rare but potentially life-threatening phenomenon.
Collapse
Affiliation(s)
| | - Faraz Siddiqui
- Pulmonary and Critical Care, Staten Island University Hospital
| | | | - Akshay Avula
- Pulmonary and Critical Care, Staten Island University Hospital
| | - Michel Chalhoub
- Pulmonary and Critical Care, Staten Island University Hospital
| |
Collapse
|
27
|
Abstract
Pure ocular presentation of Lambert–Eaton syndrome is not a common phenomenon. Such presentation poses significant diagnostic challenges and requires conscientious evaluation. In this review, we have described a case of a patient with pure ocular weakness, initially diagnosed as seronegative ocular myasthenia which on further evaluation was found to have ocular Lambert–Eaton myasthenic syndrome (LEMS).
Collapse
|
28
|
Mullaguri N, Katyal N, Sarwal A, Beary JM, George P, Karthikeyan N, Nattanamai P, Newey CR. Pitfall in Pupillometry: Exaggerated Ciliospinal Reflex in a Patient in Barbiturate Coma Mimicking a Nonreactive Pupil. Cureus 2017; 9:e2004. [PMID: 29507852 PMCID: PMC5832389 DOI: 10.7759/cureus.2004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2017] [Accepted: 12/30/2017] [Indexed: 11/05/2022] Open
Abstract
Although a neurological examination is fundamental to the evaluation of comatose patients, it is less reliable in a medically induced coma. A commonly misinterpreted finding in patients in a pentobarbital coma is altered pupillary reactivity secondary to an exaggerated ciliospinal reflex. Recognizing an exaggerated ciliospinal reflex in patients in a pentobarbital coma is important and may prevent unnecessary intervention. We present a patient induced in a pentobarbital coma for the treatment of status epilepticus who exhibited a nonreactive pupil secondary to an exaggerated ciliospinal reflex confirmed by pupillometry. We also discuss the anatomy of the ciliospinal reflex and literature regarding its clinical relevance.
Collapse
|
29
|
Katyal N, Newey CR. Does a Spontaneous Intracerebral Hemorrhage Predispose to a Secondary, Distant Intracerebral Hemorrhage? A Case Report and Review of the Literature. Cureus 2017; 9:e1999. [PMID: 29507847 PMCID: PMC5832393 DOI: 10.7759/cureus.1999] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Cerebrovascular autoregulation may be dysfunctional after acute intracerebral hemorrhage (ICH). This disruption in autoregulation can potentially result in secondary neurological damage that may present as an intracranial hemorrhage at locations distant from the primary site of hemorrhage. We discuss a case of 68-year-old female who presented with acute left hemiparesis from a spontaneous right frontal ICH. Magnetic resonance imaging (MRI) was negative for any other blooming artifact. Her weakness was improving, but after 72 hours from admission, she had an acute change in her mental status and was found to have a new left frontal ICH distant from the primary hemorrhage. Cerebral dysregulation following spontaneous ICH may predispose patients with risk factors, such as chronic hypertension, to a secondary spontaneous ICH distant from initial ICH. Recognizing this phenomenon can guide the management of acute ICH.
Collapse
|
30
|
Abstract
Movement disorders represent one of the less common presentations of cocaine toxicity observed in clinical practice. Given the magnitude of crack cocaine use, it is vital to understand the underlying pathogenesis. We present a case of a patient who clinically exhibited cocaine-induced choreoathetosis. The diagnosis was confirmed after ruling out all other organic causes of de novo choreoathetoid movement. This case highlights the association of cocaine with choreoathetoid movements. We propose a preliminary understanding of the underlying pathogenesis, which may help intensivists better recognize this uncommon phenomenon.
Collapse
Affiliation(s)
| | - Faraz Siddiqui
- Pulmonary and Critical Care, Staten Island University Hospital
| | | | | | - Michel Chalhoub
- Pulmonary and Critical Care, Staten Island University Hospital
| |
Collapse
|
31
|
Katyal N, Govindarajan R. Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement. Front Neurol 2017; 8:521. [PMID: 29033893 PMCID: PMC5626834 DOI: 10.3389/fneur.2017.00521] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 09/19/2017] [Indexed: 12/20/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a clinically progressive neurodegenerative syndrome predominantly affecting motor neurons and their associated tracts. Riluzole and edaravone are the only FDA certified drugs for treating ALS. Over the past two decades, almost all clinical trials aiming to develop a successful therapeutic strategy for this disease have failed. Genetic complexity, inadequate animal models, poor clinical trial design, lack of sensitive biomarkers, and diagnostic delays are some of the potential reasons limiting any significant development in ALS clinical trials. In this review, we have outlined the possible reasons for failure of ALS clinical trials, addressed the factors limiting timely diagnosis, and suggested possible solutions for future considerations for each of the shortcomings.
Collapse
Affiliation(s)
- Nakul Katyal
- Neurology, University of Missouri School of Medicine, University of Missouri, Columbia, MO, United States
| | - Raghav Govindarajan
- Neurology, University of Missouri School of Medicine, University of Missouri, Columbia, MO, United States
| |
Collapse
|
32
|
Wadhwa A, Katyal N, Singh NN. Abstract WP316: Stroke Simulation Improves Resident Confidence in Acute Stroke/TIA Management. Stroke 2017. [DOI: 10.1161/str.48.suppl_1.wp316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective/Background:
The goal of this study was to determine if clinical simulation improved resident confidence in delivering acute stroke care including patient interaction in acute setting, rapid neurological assessment including NIHSS and ABCD2 and medical decision making.
Design/methods:
Between 2010-2016, a total of 31 neurology residents participated in acute stroke simulation by the end of PGY-1 year before starting stroke calls.Five different case scenarios using standardized patients were used - TIA, Intraparenchymal hemorrhage, acute ischemic stroke within 3 hours, within eight hours and acute ischemic stroke with wake up symptoms.The simulation was video & audio taped. Historic controls consisting of PGY2 residents without simulation were used. Pre & post simulation survey, SP comments and debriefing was done for each scenario.
Results:
Residents reported 100 % satisfaction with quality of demonstrations and hands-on learning experience.The accuracy and timing of decision making - IV thrombolytic, No Thrombolytic and catheter based reperfusion was significantly better to historic control and pre and post simulation competency. The decision making also improved from 1
st
to the 5
th
case scenario. Significant improvement was also seen in patient interaction, utilization of NIHSS and ABCD2 score in decision making, indications and contraindications to thrombolytic, utilization of resources including CT & CTA, CT perfusion and MRI of brain, door to needle time and consulting Neurointerventionist.
Conclusion:
Simulation training using SPs is a superior teaching method in the management of acute stroke/TIA and helps to manage real life patients. Residents felt that this way of learning was superior to classroom didactics. It may be a useful teaching tool for smaller hospitals where patient volume is low, in addition to being utilized as an annual competency test.
Collapse
|
33
|
Abstract
The ketogenic diet is intended for use in patients with epilepsy whose seizures are resistant to conventional drug therapy. It is a diet high in fat and low in carbohydrate and protein content, and is intended to produce ketosis from the incomplete metabolism of fats. It is safe and effective--many patients with severe, drug-resistant epilepsy show improvement. Limiting carbohydrate intake in patients to obtain the necessary ratio of fats to carbohydrates and protein requires careful planning and, in children, parental involvement. Although the ketogenic diet is professionally planned, an unrecognized source of carbohydrates is prescription and over-the-counter medications. If the carbohydrate content of medications is overlooked, ketosis can be inhibited with potential loss of seizure control occurring. Thus, it is essential for care providers and parents to know the carbohydrate content of medications, including not only the typical sugar content, but also the content of reduced carbohydrate (e.g., glycerin). From information supplied by drug manufacturers, we determined the carbohydrate content of commonly used medications. By knowing the carbohydrate content of these often used medications, the additional carbohydrate content of the medications can be taken into account and adjustments can be made in the ketogenic diet.
Collapse
Affiliation(s)
- B McGhee
- Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pa., USA
| | | |
Collapse
|
34
|
Howrie DL, Kraisinger M, McGhee HW, Crumrine PK, Katyal N. The ketogenic diet: the need for a multidisciplinary approach. Ann Pharmacother 1998; 32:384-5. [PMID: 9533070 DOI: 10.1345/aph.17201] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|